Medinotec Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Medinotec Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $9.11M | May 29, 2025 |
| FY2025 | Feb 29, 2024 | $5.02M | May 29, 2025 |
| FY2024 | Feb 28, 2023 | $999.6K | Jul 5, 2024 |
| FY2023 | Feb 28, 2022 | $1.04M | May 30, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $4.86M | May 29, 2025 |
| FY2025 | Feb 29, 2024 | $2.44M | May 29, 2025 |
| FY2024 | Feb 28, 2023 | $581.8K | Jul 5, 2024 |
| FY2023 | Feb 28, 2022 | $455.2K | May 30, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $2.16M | May 29, 2025 |
| FY2025 | Feb 29, 2024 | ($404.7K) | May 29, 2025 |
| FY2024 | Feb 28, 2023 | ($352.7K) | Jul 5, 2024 |
| FY2023 | Feb 28, 2022 | ($124.0K) | May 30, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $3.19M | May 29, 2025 |
| FY2025 | Feb 29, 2024 | $600.6K | May 29, 2025 |
| FY2024 | Feb 28, 2023 | ($238.6K) | Jul 5, 2024 |
| FY2023 | Feb 28, 2022 | ($190.6K) | May 30, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | ($91.1K) | May 29, 2025 |
| FY2025 | Feb 29, 2024 | ($22.4K) | May 29, 2025 |
| FY2024 | Feb 28, 2023 | ($64.9K) | Jul 5, 2024 |
| FY2023 | Feb 28, 2022 | $34.8K | May 30, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $877.8K | May 29, 2025 |
| FY2025 | Feb 29, 2024 | $14.2K | May 29, 2025 |
| FY2024 | Feb 28, 2023 | ($490.5K) | Jul 5, 2024 |
| FY2023 | Feb 28, 2022 | ($137.0K) | May 30, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | ($89.0K) | May 29, 2025 |
| FY2025 | Feb 29, 2024 | ($2.3K) | May 29, 2025 |
| FY2024 | Feb 28, 2023 | $55.3K | Jul 5, 2024 |
| FY2023 | Feb 28, 2022 | ($90.6K) | May 30, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $6.81M | May 29, 2025 |
| FY2025 | Feb 29, 2024 | $4.80M | May 29, 2025 |
| FY2024 | Feb 28, 2023 | $4.49M | Jul 5, 2024 |
| FY2023 | Feb 28, 2022 | $1.32M | May 30, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $2.54M | May 29, 2025 |
| FY2025 | Feb 29, 2024 | $2.64M | May 29, 2025 |
| FY2024 | Feb 28, 2023 | $1.93M | Jul 5, 2024 |
| FY2023 | Feb 28, 2022 | $1.79M | May 30, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | $4.27M | May 29, 2025 |
| FY2025 | Feb 29, 2024 | $2.17M | May 29, 2025 |
| FY2025 | Feb 28, 2023 | $2.56M | May 29, 2025 |
| FY2024 | Feb 28, 2022 | ($470.0K) | Jul 5, 2024 |
| FY2023 | Apr 25, 2021 | ($120.1K) | May 30, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | 0 | May 29, 2025 |
| FY2025 | Feb 29, 2024 | 0 | May 29, 2025 |
| FY2024 | Feb 28, 2023 | 0 | Jul 5, 2024 |
| FY2023 | Feb 28, 2022 | 0 | May 30, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Feb 28, 2025 | 11.73M | May 29, 2025 |
| FY2025 | Mar 1, 2024 | 11.73M | May 29, 2025 |
| FY2025 | Feb 29, 2024 | 11.73M | May 29, 2025 |
| FY2025 | Mar 1, 2023 | 11.73M | May 29, 2025 |
| FY2023 | Feb 28, 2023 | 11,734 | May 30, 2023 |
| FY2024 | Feb 28, 2022 | 10.00M | Jul 5, 2024 |